Synairgen plc announced that Joseph Colliver has been appointed chief financial officer (CFO) with effect from 6 November 2023. In conjunction with this appointment and following nearly 20 years of loyal service and an orderly handover, John Ward will step down from the role of CFO on 3 November. Joseph Colliver has significant financial leadership experience, including most recently as CFO and non-executive director of several listed life sciences companies.

He has previously held CFO and senior commercial roles within the Kantar division of WPP PLC. He also has many years of experience as a consultant and in various Board roles, with a deep understanding of the strategy, governance and regulatory requirements of biotechnology companies. Full name: Joseph Tregonning Colliver; Age: 43.

Current directorships: Phytome Life Sciences Plc; Phytome Research Ltd; Hellenic Dynamics Plc; Psych Capital Plc; Colliver Advisory Ltd. Historic directorships in previous 5 years: Sativa Wellness Group Inc; Borganic Consulting Inc; Olimax NT Sp z o.o; Sativa Group Ltd; Blood Matters Ltd; Sativa Cultivation and Extraction Limited; Sativa Wellness Ltd; Phytovista Laboratories Ltd; Goodbody Botanicals Ltd; Tessellate Collective Ltd; Goodbody and Blunt Ltd; Sativa Investments Ltd; Goodbody Wellness Limited; George Botanicals Ltd; Sativa Cosmetics Ltd.